<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - APIXABAN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>APIXABAN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of venous thromboembolism following knee replacement surgery</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2.5 mg twice daily for 10&#8211;14 days, to be started 12&#8211;24 hours after surgery.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of venous thromboembolism following hip replacement surgery</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2.5 mg twice daily for 32&#8211;38 days, to be started 12&#8211;24 hours after surgery.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of deep-vein thrombosis</span>,
                <span class="indication">Treatment of pulmonary embolism</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 10 mg twice daily for 7 days, then maintenance 5 mg twice daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of recurrent deep-vein thrombosis</span>,
                <span class="indication">Prophylaxis of recurrent pulmonary embolism</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2.5 mg twice daily, following completion of 6 months anticoagulant treatment.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and at least one risk factor such as previous stroke or transient ischaemic attack, symptomatic heart failure, diabetes mellitus, hypertension, or age &#8805; 75 years</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults 18&#8211;79 years</strong><br/>
                5 mg twice daily.</li>
              <li class="dose adult"><strong>For adults 80 years and over (body-weight up to 61 kg)</strong><br/>
                2.5 mg twice daily.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>For information on changing from, or to, other anticoagulants, consult product literature.</p>
            </section>
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Apixaban is a direct inhibitor of activated factor X (factor Xa).</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid&#8212;no information available.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Avoid in severe impairment and in hepatic disease associated with coagulopathy.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>For <i>prophylaxis of stroke and systemic embolism in atrial fibrillation</i>, reduce dose to 2.5&#8239;mg twice daily if creatinine clearance 15&#8211;29&#8239;mL/minute, or if serum-creatinine &#8805;133&#8239; micromol/litre and age &#8805;80 years or body-weight &#8804;60&#8239;kg.</p>
            </section>
        
            <section class="generalInformation">
              <p>For <i>prophylaxis of venous thromboembolism following knee or hip replacement surgery, prophylaxis of recurrent deep-vein thrombosis or pulmonary embolism, and treatment of deep-vein thrombosis or pulmonary embolism</i>, use with caution if creatinine clearance 15&#8211;29&#8239;mL/ minute.</p><p>Manufacturer advises avoid if creatinine clearance less than 15&#8239;mL/minute&#8212;no information available.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Active bleeding</li>
            <li>malignant neoplasms</li>
            <li>oesophageal varices</li>
            <li>recent brain surgery</li>
            <li>recent gastro-intestinal ulcer</li>
            <li>recent intracranial haemorrhage</li>
            <li>recent ophthalmic surgery</li>
            <li>recent spine surgery</li>
            <li>significant risk of major bleeding</li>
            <li>vascular aneurysm</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Anaemia, bruising, haemorrhage, nausea,
              </p>
              <p>
                <strong>uncommon:</strong> Hypotension, rash, thrombocytopenia,
              </p>
        
        
        
      </section>



      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA245</h3>
              <p outputclass="title">Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (January 2012)</p> <p>Apixaban is an option for the prevention of venous thromboembolism in adults after elective hip or knee replacement surgery.</p><xref format="html" href="http://www.nice.org.uk/TA245">www.nice.org.uk/TA245</xref>
                <a href="http://www.nice.org.uk/TA245" target="_blank">www.nice.org.uk/TA245</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA275</h3>
              <p outputclass="title">Apixaban for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (February 2013)</p> <p>Apixaban is an option for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation in accordance with its licensed indication; with one or more of the following risk factors: </p> <ul> <li>previous stroke or transient ischaemic attack</li> <li>symptomatic heart failure</li> <li>age &#8805;75 years</li> <li>diabetes mellitus</li> <li>hypertension</li> </ul> <p>The risks and benefits of apixaban compared to warfarin, dabigatran etexilate, and rivaroxaban should be discussed with the patient.</p><xref format="html" href="http://www.nice.org.uk/TA275">www.nice.org.uk/TA275</xref>
                <a href="http://www.nice.org.uk/TA275" target="_blank">www.nice.org.uk/TA275</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA341</h3>
              <p outputclass="title">Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (June 2015)</p> <p>Apixaban is an option for the treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism in adults.</p><xref format="html" href="http://www.nice.org.uk/TA341">www.nice.org.uk/TA341</xref>
                <a href="http://www.nice.org.uk/TA341" target="_blank">www.nice.org.uk/TA341</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Anaesthesia with postoperative indwelling epidural catheter (risk of paralysis&#8212;monitor neurological signs and wait 20&#8211;30 hours after apixaban dose before removing catheter and do not give next dose until at least 5 hours after catheter removal)
          </li>
          <li>
            prosthetic heart valve (efficacy not established)
          </li>
          <li>
            risk of bleeding
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Patients should be monitored for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs.</p><p>No routine anticoagulant monitoring required (INR tests are unreliable).</p>
            </section>
      </section>


      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Duration of treatment should be determined by balancing the benefit of treatment with the bleeding risk; shorter duration of treatment (at least 3 months) should be based on transient risk factors i.e recent surgery, trauma, immobilsation.</p><p>Apixaban should not be used as an alternative to unfractionated heparin in pulmonary embolism in patients with haemodynamic instability, or who may receive thrombolysis or pulmonary embolectomy.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of APIXABAN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP77311"><a href="../medicinalForm/PHP77311.html" data-target="#PHP77311" data-action="load">Tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
